Charles Zhou
Stock Analyst at UBS
(0.69)
# 3,728
Out of 4,786 analysts
10
Total ratings
42.86%
Success rate
-12.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FUTU Futu Holdings | Maintains: Buy | $130 → $136 | $102.35 | +32.88% | 3 | Mar 17, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $16 | $11.91 | +34.34% | 1 | Mar 8, 2023 | |
| COGT Cogent Biosciences | Initiates: Buy | $15 | $5.99 | +150.42% | 1 | Jun 28, 2022 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.27 | - | 1 | May 5, 2022 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $56 | $1.09 | +5,037.61% | 1 | Aug 2, 2021 | |
| RPTX Repare Therapeutics | Initiates: Buy | $46 | $0.99 | +4,565.79% | 1 | Jun 28, 2021 | |
| QD Qudian | Downgrades: Neutral | n/a | $2.69 | - | 2 | Jan 22, 2020 |
Futu Holdings
Mar 17, 2025
Maintains: Buy
Price Target: $130 → $136
Current: $102.35
Upside: +32.88%
Zymeworks
Mar 8, 2023
Reiterates: Buy
Price Target: $16
Current: $11.91
Upside: +34.34%
Cogent Biosciences
Jun 28, 2022
Initiates: Buy
Price Target: $15
Current: $5.99
Upside: +150.42%
MacroGenics
May 5, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.27
Upside: -
PMV Pharmaceuticals
Aug 2, 2021
Initiates: Buy
Price Target: $56
Current: $1.09
Upside: +5,037.61%
Repare Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: $46
Current: $0.99
Upside: +4,565.79%
Qudian
Jan 22, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.69
Upside: -